HENLIUS(02696),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02696 HENLIUS

Market Closed 12-20 16:08:10

23.900

+0.050

+0.21%

High23.950	Low23.800	Vol610.80K
Open23.900	D1 Closing23.850	Amplitude0.63%
Mkt Cap12.99B	Tradable Cap3.90B	Total Shares543.49M
T/O14.58M	T/O Rate0.37%	Tradable Shares163.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02696","market":"HK","secType":"STK","nameCN":"HENLIUS","latestPrice":23.9,"timestamp":1734682090017,"preClose":23.85,"halted":0,"volume":610800,"delay":0,"floatShares":163000000,"shares":543494853,"eps":1.0716573554245905,"marketStatus":"Market Closed","change":0.05,"latestTime":"12-20 16:08:10","open":23.9,"high":23.95,"low":23.8,"amount":14581765,"amplitude":0.006289,"askPrice":23.9,"askSize":133300,"bidPrice":23.85,"bidSize":400,"shortable":3,"etf":0,"ttmEps":1.354188548041487,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1734917400000},"marketStatusCode":7,"adr":0,"listingDate":1569340800000,"exchange":"SEHK","adjPreClose":23.85,"openAndCloseTimeList":[[1734658200000,1734667200000],[1734670800000,1734681600000]],"volumeRatio":0.6570264069110401,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02696","defaultTab":"news","newsList":[{"id":"2492954054","title":"Shanghai Fosun Pharmaceutical Subsidiary Signs Cooperation, License Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2492954054","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492954054?lang=en_us&edition=fundamental","pubTime":"2024-12-20 16:28","pubTimestamp":1734683284,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical Group  subsidiary Henlius  signed a cooperation and license agreement with Palleon.The two parties will cooperate on developing Palleon's E-602 product and related combination therapy solutions in the field and commercialization in their respective licensed regions, according to a Thursday filing with the Shanghai bourse.Henlin shall pay Palleon royalties ranging between 8% and 12%, based on the annual net sales of the licensed products in the Henlin licensed territory.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0028","600196","BK0012","BK0175","BK0183","BK1161","BK0096","02696","BK0239","BK0060","BK0187","BK0196","BK0188","00656","BK1230"],"gpt_icon":0},{"id":"2492174899","title":"BRIEF-Shanghai Henlius Biotech Says Collaboration And License Agreement With Palleon","url":"https://stock-news.laohu8.com/highlight/detail?id=2492174899","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492174899?lang=en_us&edition=fundamental","pubTime":"2024-12-19 22:55","pubTimestamp":1734620129,"startTime":"0","endTime":"0","summary":"Dec 19 (Reuters) - Shanghai Henlius Biotech Inc :   * COLLABORATION AND LICENSE AGREEMENT WITH PALLEON FOR- E-602 AND COMBINATION THERAPYFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BRIEF-Shanghai Henlius Biotech Says Collaboration And License Agreement With Palleon","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2492140875","title":"Shanghai Henlius Biotech - Collaboration and License Agreement With Palleon for- E-602 and Combination Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2492140875","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492140875?lang=en_us&edition=fundamental","pubTime":"2024-12-19 18:31","pubTimestamp":1734604272,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nFWN3NK0CC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2492520147","title":"Fosun Pharmaceutical  Says Subsidiary Henlius Signs Collaboration and Licensing Agreement With Palleon","url":"https://stock-news.laohu8.com/highlight/detail?id=2492520147","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492520147?lang=en_us&edition=fundamental","pubTime":"2024-12-19 18:17","pubTimestamp":1734603463,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nL4N3NK0UK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0175","BK0012","BK0183","BK0196","BK0188","BK0060","02696","600196","BK0028","BK1161","BK0187","BK0239","BK0096"],"gpt_icon":0},{"id":"2492147427","title":"BRIEF-Fosun Pharmaceutical's Subsidiary Signs Agreement With Palleon","url":"https://stock-news.laohu8.com/highlight/detail?id=2492147427","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492147427?lang=en_us&edition=fundamental","pubTime":"2024-12-19 18:17","pubTimestamp":1734603463,"startTime":"0","endTime":"0","summary":"BRIEF-Fosun Pharmaceutical's Subsidiary Signs Agreement With PalleonDec 19  - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:SAYS SUBSIDIARY SHANGHAI HENLIUS BIOTECH INC SIGNS COLLABORATION AND LICENSING AGREEMENT WITH PALLEON PHARMACEUTICALS INCSource textFurther company coverage: 600196.SS  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nL4N3NK0UK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600196","BK0196","BK0096","BK0187","02696","BK0060","BK0239","BK1161","BK0028","BK0188","BK0175","BK0012","BK0183"],"gpt_icon":0},{"id":"2492136081","title":"High Growth Tech Stocks Including Shanghai Henlius Biotech","url":"https://stock-news.laohu8.com/highlight/detail?id=2492136081","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492136081?lang=en_us&edition=fundamental","pubTime":"2024-12-19 09:06","pubTimestamp":1734570419,"startTime":"0","endTime":"0","summary":"As global markets experience fluctuations with major indexes like the Nasdaq Composite reaching new highs, small-cap stocks face challenges as evidenced by the Russell 2000's recent underperformance. Amidst these dynamics, high growth tech stocks such as Shanghai Henlius Biotech stand out by leveraging innovation and adaptability to navigate economic shifts and investor expectations.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/4422000-choice1-main-header/1585186589176","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/4422000-choice1-main-header/1585186589176"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/cn/media/szse-000681/visual-china-groupltd-shares/news/high-growth-tech-stocks-including-shanghai-henlius-biotech","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2489504487","title":"BRIEF-UBS Group's Short Position In Shanghai Henlius Biotech Reduced To 0% On Dec 2 From 2.07% - HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2489504487","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489504487?lang=en_us&edition=fundamental","pubTime":"2024-12-05 17:18","pubTimestamp":1733390280,"startTime":"0","endTime":"0","summary":"Dec 5 (Reuters) - HKEX:   * UBS GROUP'S SHORT POSITION IN SHANGHAI HENLIUS BIOTECH  REDUCED TO 0% ON DEC 2 FROM 2.07% - HKEX Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2489878044","title":"UBS Group's Short Position in Shanghai Henlius Biotech  Reduced to 0% on Dec 2 From 2.07% - HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2489878044","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489878044?lang=en_us&edition=fundamental","pubTime":"2024-12-05 17:11","pubTimestamp":1733389863,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241205:nFWN3N51ZO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2488416711","title":"BRIEF-Shanghai Henlius Biotech Updates On NDA For New Indication Of Hansizhuang","url":"https://stock-news.laohu8.com/highlight/detail?id=2488416711","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488416711?lang=en_us&edition=fundamental","pubTime":"2024-12-04 20:24","pubTimestamp":1733315054,"startTime":"0","endTime":"0","summary":"Dec 4 (Reuters) - Shanghai Henlius Biotech Inc :   * NDA FOR NEW INDICATION OF HANSIZHUANG (SERPLULIMAB INJECTION) IN COMBINATION WITH CHEMOTHERAPY APPROVED BY NMPA Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2488164523","title":"Henlius Gets Chinese Regulator's Go-Ahead for Phase 2 Clinical Trial of Tumor Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2488164523","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488164523?lang=en_us&edition=fundamental","pubTime":"2024-12-04 19:48","pubTimestamp":1733312917,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech's  application for the phase 2 clinical trial of HLX22 in two different kinds of combinations has been approved by China's National Medical Products Administration, a Wednesday bourse filing said.The drug is being tested in combination with trastuzumab and chemotherapy or combined with trastuzumab deruxtecan for the treatment of HER2-expressing solid tumors.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2488164824","title":"Henlius Gets Chinese Regulator's Approval for Clinical Trial of Tumor Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2488164824","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488164824?lang=en_us&edition=fundamental","pubTime":"2024-12-04 19:44","pubTimestamp":1733312693,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech's (HKG:2696) application for the phase 1b/2 clinical trial of HLX43 for injection has been approved by China's National Medical Products Administration, a Wednesday bourse fil","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2488161000","title":"Henlius Secures Chinese Regulator's Nod for New Drug Application for Breast Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2488161000","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488161000?lang=en_us&edition=fundamental","pubTime":"2024-12-04 19:44","pubTimestamp":1733312641,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech's  new drug application  for HLX11 has been accepted by China's National Medical Products Administration, a Wednesday bourse filing said.Of the two indications included in the NDA, the first is the use of the drug in combination with trastuzumab and chemotherapy as adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence.The second indication is the use of HLX11 in combination with trastuzumab and docetaxel to treat patients with HER2-positive, metastatic, or unresectable local recurrent breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2488166476","title":"Shanghai Henlius Biotech's NDA for Lung Cancer Drug's New Indication Gets Chinese Regulator's Nod","url":"https://stock-news.laohu8.com/highlight/detail?id=2488166476","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488166476?lang=en_us&edition=fundamental","pubTime":"2024-12-04 19:04","pubTimestamp":1733310262,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech's  new drug application  for a new indication of its Serplulimab injection has been approved by China's National Medical Products Administration, a Wednesday bourse filing said.The NDA has been approved for Serplulimab in combination with pemetrexed and carboplatin for the first-line treatment of patients with unresectable locally advanced or metastatic non-squamous non-small cell lung cancer.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2488631461","title":"BRIEF-Shanghai Henlius Biotech Inc's Application For Phase 1B/2 Clinical Trial Of HLX43- For Injection Approved By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2488631461","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488631461?lang=en_us&edition=fundamental","pubTime":"2024-12-04 18:32","pubTimestamp":1733308370,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Henlius Biotech Inc's Application For Phase 1B/2 Clinical Trial Of HLX43- For Injection Approved By NMPADec 4 (Reuters) - Shanghai Henlius Biotech Inc 2696.HK:APPLICATION FOR PHASE 1B/2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nFWN3N41A1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2488416365","title":"BRIEF-Shanghai Henlius Biotech Says New Drug Application For Pertuzumab Biosimilar- HLX11 Accepted By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2488416365","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488416365?lang=en_us&edition=fundamental","pubTime":"2024-12-04 18:26","pubTimestamp":1733307964,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Henlius Biotech Says New Drug Application For Pertuzumab Biosimilar- HLX11 Accepted By NMPADec 4  - Shanghai Henlius Biotech Inc 2696.HK:NEW DRUG APPLICATION FOR PERTUZUMAB BIOSIMILAR- HLX11 ACCEPTED BY NMPAFurther company coverage: 2696.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nFWN3N419X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2488168849","title":"Shanghai Henlius Biotech Inc - Application for Phase 1B/2 Clinical Trial of Hlx43- for Injection Approved by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2488168849","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488168849?lang=en_us&edition=fundamental","pubTime":"2024-12-04 18:03","pubTimestamp":1733306612,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nFWN3N41A1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2488150465","title":"Shanghai Henlius Biotech - Nda for New Indication of Hansizhuang (Serplulimab Injection) in Combination With Chemotherapy Approved by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2488150465","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488150465?lang=en_us&edition=fundamental","pubTime":"2024-12-04 17:55","pubTimestamp":1733306110,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nFWN3N5136:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2488835150","title":"Shanghai Henlius Biotech Inc - New Drug Application for Pertuzumab Biosimilar- Hlx11 Accepted by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2488835150","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488835150?lang=en_us&edition=fundamental","pubTime":"2024-12-04 17:49","pubTimestamp":1733305778,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nFWN3N419X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2488990785","title":"New Indication of Henlius' Lung Cancer Drug Given Green Light by Chinese Regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=2488990785","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488990785?lang=en_us&edition=fundamental","pubTime":"2024-12-03 19:09","pubTimestamp":1733224173,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech's  new drug application for a new indication of HANSIZHUANG in combination with pemetrexed and carboplatin has been approved by China's National Medical Products Administration, a Tuesday bourse filing said.The new indication of the drug in combination with pemetrexed and carboplatin is for the first-line treatment of patients with unresectable locally advanced or metastatic non-squamous non-small cell lung cancer.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2488499019","title":"BRIEF-Shanghai Henlius Biotech Says NMPA Approved NDA For New Indication Of Hansizhuang","url":"https://stock-news.laohu8.com/highlight/detail?id=2488499019","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488499019?lang=en_us&edition=fundamental","pubTime":"2024-12-03 19:06","pubTimestamp":1733223988,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Henlius Biotech Says NMPA Approved NDA For New Indication Of HansizhuangDec 3 (Reuters) - Shanghai Henlius Biotech 2696.HK:NDA FOR NEW INDICATION OF HANSIZHUANG IN COMBINATION WITH CHEMOTHERAPY APPROVED BY NMPAFurther company coverage: 2696.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241203:nFWN3N319W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696","BK1161"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0766},{"period":"1month","weight":0.1744},{"period":"3month","weight":0.0369},{"period":"6month","weight":0.2686},{"period":"1year","weight":1.0323},{"period":"ytd","weight":0.7194}],"compareEarnings":[{"period":"1week","weight":-0.0125},{"period":"1month","weight":0.0008},{"period":"3month","weight":0.0801},{"period":"6month","weight":0.0939},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.1568}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Shanghai Henlius Biotech Inc. is a China-based company principally involved in the research, development, production and sales of monoclonal antibody products. The Company’s main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) biosimilar HLX02, Humira (adalimumab) biosimilar HLX03 and Avastin (bevacizumab) biosimilar HLX04, as well as bio-innovative drug candidates, including HLX06 (a novel VEGFR2 inhibitor), HLX07 (an EGFR inhibitor), HLX10 (a novel PD-1 inhibitor), HLX20 (a novel PD-L1 inhibitor) and HLX22 (a novel HER2 inhibitor), among others. The Company is also engaged in the provision of related technical services. The Company operates its businesses primarily in Mainland China and the United States.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.004462},{"month":2,"riseRate":0.6,"avgChangeRate":0.003175},{"month":3,"riseRate":0.4,"avgChangeRate":-0.070667},{"month":4,"riseRate":0.8,"avgChangeRate":0.127521},{"month":5,"riseRate":0.4,"avgChangeRate":-0.068918},{"month":6,"riseRate":0.6,"avgChangeRate":0.1049},{"month":7,"riseRate":0.4,"avgChangeRate":0.0182},{"month":8,"riseRate":0.4,"avgChangeRate":-0.051626},{"month":9,"riseRate":0,"avgChangeRate":-0.146246},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.017718},{"month":11,"riseRate":0.666667,"avgChangeRate":0.070363},{"month":12,"riseRate":0.833333,"avgChangeRate":0.002729}],"exchange":"SEHK","name":"HENLIUS","nameEN":"HENLIUS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"HENLIUS(02696),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest HENLIUS(02696) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"HENLIUS,02696,HENLIUS股票,HENLIUS股票老虎,HENLIUS股票老虎国际,HENLIUS行情,HENLIUS股票行情,HENLIUS股价,HENLIUS股市,HENLIUS股票价格,HENLIUS股票交易,HENLIUS股票购买,HENLIUS股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"HENLIUS(02696),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest HENLIUS(02696) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}